Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 952,300 shares, a growth of 14.4% from the December 15th total of 832,200 shares. Based on an average daily trading volume, of 94,200 shares, the days-to-cover ratio is presently 10.1 days. Currently, 4.4% of the company’s shares are sold short.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 16,054 shares of company stock valued at $185,897 over the last 90 days. 19.52% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in shares of Gyre Therapeutics during the third quarter worth about $334,000. WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics during the second quarter worth about $220,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics during the second quarter worth about $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Trading Up 1.4 %

NASDAQ GYRE traded up $0.15 during trading hours on Friday, reaching $10.95. The company had a trading volume of 48,956 shares, compared to its average volume of 116,811. The stock has a 50-day moving average of $11.57 and a 200 day moving average of $12.64. Gyre Therapeutics has a 1-year low of $8.26 and a 1-year high of $26.37.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.